Frankfurt: German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema.
Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales.
The injection, which Bayer is co-developing with Regeneron, is already approved for other eye diseases. ($1 = 0.7392 euros).
Telangana: Train, bus collision kills 16
Modi will develop India into Hindu state: Goa Minister
DNA: The unforgettable story of Kargil war
Is BJP trying to develop India as a Hindu nation?